vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Goosehead Insurance, Inc. (GSHD). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $93.1M, roughly 2.0× Goosehead Insurance, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 8.6%, a 4.7% gap on every dollar of revenue. On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs -1.8%). Over the past eight quarters, Goosehead Insurance, Inc.'s revenue compounded faster (9.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.
AMPH vs GSHD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $93.1M |
| Net Profit | $24.4M | $8.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 16.1% |
| Net Margin | 13.3% | 8.6% |
| Revenue YoY | -1.8% | 23.1% |
| Net Profit YoY | -35.7% | 204.0% |
| EPS (diluted) | $0.51 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $93.1M | ||
| Q4 25 | $183.1M | $105.3M | ||
| Q3 25 | $191.8M | $90.4M | ||
| Q2 25 | $174.4M | $94.0M | ||
| Q1 25 | $170.5M | $75.6M | ||
| Q4 24 | $186.5M | $93.9M | ||
| Q3 24 | $191.2M | $78.0M | ||
| Q2 24 | $182.4M | $78.1M |
| Q1 26 | — | $8.0M | ||
| Q4 25 | $24.4M | $12.4M | ||
| Q3 25 | $17.4M | $7.9M | ||
| Q2 25 | $31.0M | $5.2M | ||
| Q1 25 | $25.3M | $2.3M | ||
| Q4 24 | $38.0M | $14.9M | ||
| Q3 24 | $40.4M | $7.6M | ||
| Q2 24 | $37.9M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 19.4% | 29.4% | ||
| Q3 25 | 13.2% | 23.5% | ||
| Q2 25 | 24.2% | 16.7% | ||
| Q1 25 | 21.9% | 8.8% | ||
| Q4 24 | 24.2% | 29.7% | ||
| Q3 24 | 29.8% | 21.1% | ||
| Q2 24 | 30.3% | 19.7% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | 13.3% | 11.8% | ||
| Q3 25 | 9.0% | 8.7% | ||
| Q2 25 | 17.8% | 5.5% | ||
| Q1 25 | 14.8% | 3.1% | ||
| Q4 24 | 20.4% | 15.8% | ||
| Q3 24 | 21.1% | 9.7% | ||
| Q2 24 | 20.8% | 7.9% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $0.51 | $0.48 | ||
| Q3 25 | $0.37 | $0.29 | ||
| Q2 25 | $0.64 | $0.18 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $0.58 | ||
| Q3 24 | $0.78 | $0.29 | ||
| Q2 24 | $0.73 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $25.7M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $-121.3M |
| Total Assets | $1.6B | $392.8M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $25.7M | ||
| Q4 25 | $282.8M | $34.4M | ||
| Q3 25 | $276.2M | $51.6M | ||
| Q2 25 | $231.8M | $92.4M | ||
| Q1 25 | $236.9M | $70.2M | ||
| Q4 24 | $221.6M | $54.3M | ||
| Q3 24 | $250.5M | $47.5M | ||
| Q2 24 | $217.8M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $289.5M | ||
| Q3 25 | $608.6M | $290.0M | ||
| Q2 25 | $607.7M | $289.8M | ||
| Q1 25 | $603.9M | $290.3M | ||
| Q4 24 | $601.6M | $82.3M | ||
| Q3 24 | $596.4M | $84.6M | ||
| Q2 24 | $586.9M | $87.0M |
| Q1 26 | — | $-121.3M | ||
| Q4 25 | $788.8M | $-95.5M | ||
| Q3 25 | $776.7M | $-105.0M | ||
| Q2 25 | $757.5M | $-78.6M | ||
| Q1 25 | $751.3M | $-88.5M | ||
| Q4 24 | $732.3M | $43.9M | ||
| Q3 24 | $727.7M | $58.3M | ||
| Q2 24 | $713.3M | $39.8M |
| Q1 26 | — | $392.8M | ||
| Q4 25 | $1.6B | $414.9M | ||
| Q3 25 | $1.7B | $403.6M | ||
| Q2 25 | $1.6B | $436.6M | ||
| Q1 25 | $1.6B | $412.6M | ||
| Q4 24 | $1.6B | $397.7M | ||
| Q3 24 | $1.5B | $358.1M | ||
| Q2 24 | $1.5B | $338.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.87× | ||
| Q3 24 | 0.82× | 1.45× | ||
| Q2 24 | 0.82× | 2.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $91.8M | ||
| Q3 25 | $52.6M | $24.2M | ||
| Q2 25 | $35.6M | $28.9M | ||
| Q1 25 | $35.1M | $15.5M | ||
| Q4 24 | $29.0M | $71.5M | ||
| Q3 24 | $60.0M | $28.1M | ||
| Q2 24 | $69.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $86.1M | ||
| Q3 25 | $47.2M | $23.7M | ||
| Q2 25 | $25.0M | $27.2M | ||
| Q1 25 | $24.4M | $14.9M | ||
| Q4 24 | $16.6M | $70.6M | ||
| Q3 24 | $46.2M | $28.0M | ||
| Q2 24 | $63.1M | $18.6M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 81.8% | ||
| Q3 25 | 24.6% | 26.2% | ||
| Q2 25 | 14.3% | 28.9% | ||
| Q1 25 | 14.3% | 19.7% | ||
| Q4 24 | 8.9% | 75.1% | ||
| Q3 24 | 24.1% | 35.9% | ||
| Q2 24 | 34.6% | 23.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 5.4% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 1.0% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 7.38× | ||
| Q3 25 | 3.03× | 3.06× | ||
| Q2 25 | 1.15× | 5.61× | ||
| Q1 25 | 1.39× | 6.61× | ||
| Q4 24 | 0.76× | 4.82× | ||
| Q3 24 | 1.48× | 3.72× | ||
| Q2 24 | 1.82× | 3.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GSHD
| Renewal Royalty Fees (2) | $43.6M | 47% |
| Renewal Commissions (1) | $18.2M | 20% |
| Contingent Commissions (1) | $10.7M | 11% |
| New Business Royalty Fees (2) | $7.9M | 8% |
| New Business Commissions (1) | $7.5M | 8% |
| Other | $3.7M | 4% |
| Initial Franchise Fees (2) | $1.6M | 2% |
